|
C20ORF43 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.63946634046397E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.90398865749376E-14 |
| Normal-vs-Stage2 |
5.029900E-04 |
| Normal-vs-Stage3 |
2.10609307771392E-13 |
| Normal-vs-Stage4 |
5.89084336866108E-12 |
| Stage1-vs-Stage2 |
1.172070E-02 |
| Stage1-vs-Stage3 |
1.804550E-01 |
| Stage1-vs-Stage4 |
6.442200E-02 |
| Stage2-vs-Stage3 |
2.757600E-03 |
| Stage2-vs-Stage4 |
2.040600E-03 |
| Stage3-vs-Stage4 |
4.656800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.22124532708767E-15 |
| Normal-vs-AfricanAmerican |
5.740600E-03 |
| Normal-vs-Asian |
1.95670002423043E-09 |
| Caucasian-vs-AfricanAmerican |
5.960100E-02 |
| Caucasian-vs-Asian |
4.038200E-01 |
| AfricanAmerican-vs-Asian |
3.285600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.10356168647741E-13 |
| Normal-vs-Female |
9.64783808399261E-14 |
| Male-vs-Female |
1.654770E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.67943436935047E-12 |
| Normal-vs-Age(41-60Yrs) |
4.26214619153598E-13 |
| Normal-vs-Age(61-80Yrs) |
5.35305133553265E-12 |
| Normal-vs-Age(81-100Yrs) |
4.792100E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.701800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.983600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.516200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.163400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.211400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.718400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.784800E-03 |
| Classical-VS-Follicular |
8.867500E-02 |
| Classical-VS-Other |
4.984600E-01 |
| Classical-VS-Normal |
1.62925228863742E-12 |
| Tall-VS-Follicular |
2.815000E-04 |
| Tall-VS-Other |
4.600800E-01 |
| Tall-VS-Normal |
1.69897429458388E-12 |
| Follicular-VS-Other |
3.126400E-01 |
| Follicular-VS-Normal |
1.74539999997503E-06 |
| Other-VS-Normal |
1.421800E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.34254846023896E-12 |
| Normal-vs-N1 |
6.66133814775094E-16 |
| N0-vs-N1 |
8.4789000000085E-05 |
|
|
